The feasibility study of pharmacokinetics and immune response of T-DM1 in metastatic/recurrent HER2-positive breast cancer
Not Applicable
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000018630
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
a) Brain metastasis with clinical symptoms b) Uncontrollable body fluid c) Concurrent serious disease or condition Active infection concurrent serious psychiatric disorder Ileus, breeding Uncontrollable angina and mycardial infarction within 3 months, severe heart disease with heart failure d) pregnant or lactating women e) Patient considered irrelevant by attending physician for the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetics and immune response of T-DM1
- Secondary Outcome Measures
Name Time Method